drugset / Trial / NCT04831944

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.

NCT04831944

Phase 1 Completed 21 enrolled Incyte Corporation
Non-randomizedParallel-groupOpen-labelOther

Summary

The purpose of the study is to evaluate the pharmacokinetics and safety of parsaclisib in participants With normal hepatic function and participants with hepatic impairment.

Timeline

Start
2021-03-29
Primary completion
2022-03-10
Completion
2022-03-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Parsaclisib Small molecule Oral

Indications